Momenta Pharmaceuticals’ M923, a proposed adalimumab (Humira) biosimilar, showed bioequivalent pharmacokinetics (PK) and similar safety and tolerability to both EU- and US-licensed Humira in healthy subjects, according to findings from a phase 1 study published today in Pharmacology Research and Perspectives.
Momenta Pharmaceuticals’ M923, a proposed adalimumab (Humira) biosimilar, showed bioequivalent pharmacokinetics (PK) and similar safety and tolerability to both EU- and US-licensed Humira in healthy subjects, according to findings from a phase 1 study published today in Pharmacology Research and Perspectives.
The first-in-human study was a randomized, double-blind, 3-arm, single-dose study conducted in 324 healthy subjects at 3 sites in the United Kingdom. Subjects were randomized to receive a 40 mg subcutaneous injection of either M923 or 1 of the 2 reference products (US- or EU-licensed Humira) and were followed for 71 days. Blood samples were taken pre-dose and at multiple intervals to day 71.
The study’s primary endpoints were maximum observed concentration (Cmax), area under the curve (AUC) from time 0 extrapolated to infinity (AUC0-inf), and AUC from time 0 to 336 hours (AUC0-336). Secondary endpoints included safety and immunogenicity, which were assessed throughout the study.
The researchers found that the geometric least squares means ratios (GMR) were the following between the M923 and EU-licensed and US-licensed reference arms, respectively:
The 90% confidence intervals of all GMRs fell within pre-specified confidence bounds of 80% to 125%.
Of the 324 subjects, 164 had any adverse events (AE), with 52, 55, and 57 AEs occurring in the M923, US-licensed reference, and EU-licensed reference arms, respectively. Most AEs (124) were considered mild. The most common adverse events reported were headache, nasopharyngitis, and oropharyngeal pain.
The proportion of confirmed anti-drug antibody responses in the 3 study arms was 78.0%, 73.1%, and 75.7% at day 71 for the M923, US-licensed, and EU-licensed arms, respectively.
The researchers concluded that M923 had similar PK to both US- and EU-licensed references in healthy patients, and that no meaningful differences in safety of immunogenicity were observed. These results, they say, support the initiation of confirmatory and supportive studies for the development of the proposed biosimilar.
The study was funded by Baxalta US Inc, a division of Shire. In 2016, Shire terminated its biosimilar collaboration with Momenta following its merger with Baxalta. Shire was obligated to continue to fund Momenta’s development program for M923 until the agreement’s termination. After providing a formal notice, Shire began a transfer of all ongoing clinical, regulatory, and commercialization activities for the proposed biosimilar.
Skyrizi Overtakes Humira: “Product Hopping” Leaves Biosimilar Market in Limbo
November 7th 2024For the first time, Skyrizi (risankizumab-rzaa) has replaced Humira (reference adalimumab) as AbbVie’s sales driver, largely due to companies encouraging “product hopping” to avoid competition, creating concerns for the sustainability of the burgeoning adalimumab biosimilar market.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
Eye on Pharma: Henlius, Organon Updates; Meitheal Portfolio Expansion; Celltrion Zymfentra Data
November 5th 2024Henlius and Organon’s pertuzumab biosimilar met phase 3 goals; Meitheal expanded its US biosimilars; Celltrion’s subcutaneous infliximab (Zymfentra) showed monotherapy could be as effective as combination therapy for inflammatory bowel disease.
Insights from Festival of Biologics: Dracey Poore Discusses Cardinal Health’s 2024 Biosimilar Report
May 19th 2024The discussion highlights key emerging trends from the Festival of Biologics conference and the annual Cardinal Health Biosimilars Report, including the importance of sustainability in the health care landscape and the challenges and successes in biosimilar adoption and affordability.
Phase 3 Study Reports Similar Efficacy Between SB17, Stelara in Psoriasis
October 19th 2024A phase 3, 28-week comparative clinical trial in patients with moderate to severe plaque psoriasis confirmed similarity of the proposed ustekinumab biosimilar SB17 (Samsung Bioepis) to the reference product (Stelara) in efficacy, safety, pharmacokinetics, and immunogenicity.
Eye on Pharma: Aflibercept Legal Drama; PBM, Humira Biosimilars; Denosumab Regulatory Review
October 15th 2024Regeneron appeals legal decision after judge refuses to block an aflibercept biosimilar; Prime Therapeutics, a pharmacy benefit manager (PBM), becomes the latest to offer biosimilars referencing Humira (adalimumab) at a low cost; the FDA and European Medicines Agency accept a denosumab biosimilar candidate for review.